Table 7.
Clinicopathological parameters analysis according to rs1966265 genetic polymorphism in breast cancer patients
| Clinicopathological parameters | rs1966265(N = 90) | ||||
|---|---|---|---|---|---|
| GG | AG &AA | OR | 95%CI | P | |
| T-status,n(%) | |||||
| ≤ T2 | 3(3.3) | 3(3.3) | |||
| > T2 | 17(18.9) | 67(74.4) | 3.941 | 0.730–21.284 | 0.111 |
| N-status,n(%) | |||||
| N0+ N1 | 15(6.7) | 55(61.1) | |||
| N2+ N3 | 5(5.6) | 15(16.7) | 0.818 | 0.256–2.615 | 0.735 |
| Tumor grade | |||||
| GradeII | 8(8.9) | 26(28.9) | |||
| GradeIII | 12(13.3) | 44(48.9) | 1.128 | 0.408–3.121 | 0.816 |
| ER | |||||
| positive | 16(17.8) | 46(51.1) | |||
| negative | 4(4.4) | 24(26.7) | 2.087 | 0.628–6.941 | 0.230 |
| PR | |||||
| positive | 13(14.4) | 38(42.2) | |||
| negative | 7(7.8) | 32(35.6) | 1.564 | 0.557–4.390 | 0.396 |
| Her2-neu stastus | |||||
| positive | 7(7.8) | 25(27.8) | |||
| negative | 13(14.4) | 45(50.0) | 0.969 | 0.342–2.744 | 0.953 |
| TNBC | |||||
| Yes | 3(3.3) | 13(14.4) | |||
| No | 17(18.9) | 57(63.3) | 1.292 | 0.328–5.072 | 0.713 |
| P63 | |||||
| positive | 2(2.2) | 1(1.1) | |||
| negative | 18(20.0) | 69(76.7) | 7.667 | 0.658–89.367 | 0.104 |
| Ki-67 | |||||
| positive | 3(3.3) | 25(27.8) | |||
| negative | 17(18.9) | 45(50.0) | 0.318 | 0.085–1.190 | 0.089 |
T tumor stage, N nodes stage, TNBC triple negative breast cancer, Her 2 human epidermal growth factor receptor 2